Infliximab for Injection (Leiting) 100?mg – Low price wholesale comparison

Infliximab for Injection (Leiting) 100?mg – Low price wholesale comparison

$1.00

Infliximab for Injection (Leiting®) is a 100?mg/vial formulation provided in packs of 8. Manufactured by Taizhou Mabpharm (CMAB008), this anti-TNF?? biosimilar is NMPA-approved under S20210025. Ideal for in vitro and in vivo research on autoimmune conditions. Laboratory use only.?Please consult staff for price, other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

描述

Infliximab is a chimeric monoclonal antibody targeting TNF??, widely used in biomedical research to model and treat inflammatory and autoimmune diseases like rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. The Leiting® brand (CMAB008) is China’s first domestically manufactured infliximab biosimilar, produced via CHO cell expression with demonstrated similarity in safety and efficacy.

Provided in 100?mg/vial × 8 vials per box, this injectable formulation is ideal for researchers studying cytokine inhibition, inflammatory cascade modulation, and anti-TNF therapeutic mechanisms. Produced by Taizhou Mabpharm Co., Ltd. and approved under NMPA S20210025, this product also holds rapid GMP recognition for overseas markets .

?? For laboratory research only. Not for clinical, therapeutic, diagnostic, or veterinary use.


Infliximab for Injection Product Specifications

Parameter Details
Product Name Infliximab for Injection (Leiting®)
Generic Name Infliximab
CAS Number 170277?31?3
Molecular Type Chimeric anti-TNF?? monoclonal antibody
Formulation Lyophilized powder for IV injection
Strength 100?mg per vial
Package 8 vials per box
Approval Number S20210025 (China NMPA)
Product Code/Base 86981463000014 ([barcode pending]; contact for details)
Manufacturer Taizhou Mabpharm Co., Ltd. (China)
Intended Use Laboratory research only
Storage Conditions Store 2–8?°C, protect from light; reconstitute before use

Infliximab for Injection Mechanism & Research Applications

Infliximab binds and neutralizes TNF??, disrupting inflammatory signaling pathways. Common research uses include:

  • Autoimmune disease modeling (RA, AS, PsA, IBD)

  • Cytokine release and NF??B signaling studies

  • Inflammation, pain, and immune modulation research

  • Preclinical evaluation of biosimilar efficacy and immunogenicity


Infliximab for Injection Side Effects (Observed in Research Models)

  • Elevated infection susceptibility (bacterial, fungal)

  • Infusion-like reactions: chills, fever, hypotension

  • Hematologic changes, transient hepatic enzyme elevation

  • Autoimmune-like effects such as lupus-like syndromes

  • Rare risk of lymphoma or demyelinating disorders with high/chronic dosing


Infliximab for Injection Safety & Handling

  • Use Restriction: Strictly for laboratory research; not for clinical or veterinary use

  • PPE: Use gloves, lab coat, and safety goggles

  • Storage: Keep refrigerated at 2–8?°C; do not freeze

  • Preparation: Reconstitute under aseptic conditions

  • Disposal: Follow institution’s hazardous biological waste protocols


Core Keywords

Infliximab biosimilar China, Leiting infliximab S20210025, 100?mg infliximab research, anti-TNF antibody lab use, Mabpharm infliximab CMAB008, wholesale infliximab vials, TNF?alpha inhibition research agent, lab-grade infliximab injection


Research Use Disclaimer

This product is intended only for laboratory research purposes. It is not approved for clinical, diagnostic, therapeutic, or veterinary use. Non-approved use may lead to regulatory and health risks. Users should follow institutional biosafety and handling protocols rigorously.

其他信息

重量 1 公斤
尺寸 28 × 25 × 28 厘米

评价

目前还没有评价

成为第一个“Infliximab for Injection (Leiting) 100?mg – Low price wholesale comparison” 的评价者

您的邮箱地址不会被公开。 必填项已用 * 标注

EMI Options

Select at least 2 products
to compare